Developing novel strategies against tuberculosis and malaria

Tuberculosis and malaria are among the deadliest infectious diseases worldwide and are increasingly spreading, not least due to climate change. In both cases, antimicrobial resistance renders established active substances ineffective. To ensure that effective drugs are still available in the future, researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) are working together with Evotec, a leading company for drug research and development, on resistance-breaking anti-infectives based on natural products. The research project of the team led by Prof. Rolf Müller now receives 3.1 million euros in funding from the Bill & Melinda Gates Foundation. In addition, the HIPS has been accepted as a member of the renowned „Tuberculosis Drug Accelerator“. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/developing-novel-strategies-against-tuberculosis-and-malaria-6372

Weiterlesen

Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV

Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has expanded its relationship with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) serving the US Government and biopharmaceutical industry.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-expands-development-and-manufacturing-agreement-with-abl-for-broadly-neutralising-antibodies-against-hiv-6370

Weiterlesen

Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies

Evotec SE today announced that the Company has joined forces with the Crohn’s & Colitis Foundation (“the Foundation”), the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease (“IBD”), which includes Crohn’s disease and ulcerative colitis.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-crohns–colitis-foundation-enter-agreement-to-advance-drug-discovery-for-novel-ibd-therapies-6366

Weiterlesen

Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb

Evotec SE today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-progress-in-strategic-neuroscience-partnership-with-bristol-myers-squibb-6364

Weiterlesen

Evotec announces CEO transition

Evotec SE today announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue to serve until the end of his current term (March 2026), for personal reasons. The Supervisory Board has accepted his resignation from his office. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-ceo-transition-6358

Weiterlesen

Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes

Evotec SE announced today that the Company has received a US$ 2.5 m grant from the Bill & Melinda Gates Foundation (“the foundation”) for its teratogenicity platform, and joins the foundation’s prestigious Global Health Discovery Collaboratory (“GHDC”), a network of researchers, centres of excellence, and technology platforms working together to accelerate the discovery and translation of global health interventions. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-us-25-m-grant-to-leverage-human-ipsc-derived-teratogenicity-platform-for-global-health-programmes-6356

Weiterlesen

Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases

Evotec SE announced today that the Company has entered a partnership with Charité – Universitätsmedizin Berlin (“Charité”), one of the leading and largest university hospitals in Europe, to generate a molecular patient database for ANCA-associated vasculitis (“AAV”), a collection of relatively rare autoimmune diseases of unknown cause, characterised by inflammation of blood vessels. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-partnership-with-charite-to-expand-molecular-patient-database-in-autoimmune-diseases-6354

Weiterlesen

Evotec-partner Jingxin receives approval for EVT201 in China

Evotec SE announced today that Zhejiang Jingxin Pharmaceutical Co., Ltd (“Jingxin”) has received the approval from the Chinese National Medical Products Administration (“NMPA”) for the novel insomnia treatment EVT201, also known as Dimdazenil in China.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-jingxin-receives-approval-for-evt201-in-china-6352

Weiterlesen
1 2 3 49